News

Inebilizumab ‘MITIGATES’ Flare Risk in IgG4-Related Disease

by  •  • 0 Comments
Inebilizumab-cdon reduced the risk for flares by 87% in patients with IgG4-RD, the MITIGATE study showed.
Medscape Medical News